BUYINS.NET: Market Maker Surveillance Report. Top 6 Winning Stocks With Lowest Price Friction For February 2, 2009

Feb 03, 2009 (M2 PRESSWIRE via COMTEX) -- TNH | Quote | Chart | News | PowerRating -- BUYINS.NET, www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for February 2, 2009. Since late October market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This "fair market making" requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 3,130 companies with "abnormal" market making, 2,196 companies with positive Friction Factors and 2,884 companies with negative Friction Factors. Here is a list of the top 6 companies with the largest dollar gain per share Monday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. OSI Pharmaceuticals (NASDAQ: OSIP), Apollo Group (NASDAQ: APOL), Terra Nitrogen (NYSE: TNH), Humana (NYSE: HUM), Biogen Idec (NASDAQ: BIIB | Quote | Chart | News | PowerRating) and Express Scripts (NASDAQ: ESRX). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net.

Market Maker Friction Factor is shown in the chart below:

Symbol Change % BuyVol Buy% SellVol Sell% NetVol Friction

OSIP $5.10 14.33% 993,880 55.30% 791,462 44.04% 202,418 397

APOL $4.65 5.71% 2,899,525 51.28% 2,694,025 47.65% 205,500 442

TNH $4.41 3.60% 45,133 40.59% 38,340 34.48% 6,793 15

HUM $2.62 6.91% 2,487,135 33.56% 2,345,998 31.66% 141,137 539

BIIB $2.49 5.12% 1,572,809 50.79% 1,441,718 46.56% 131,091 526

ESRX $2.49 4.63% 1,455,261 49.92% 1,372,089 47.07% 83,172 334

Click here to view chart: http://www.buyins.com/ff/fftopg2-2-09.jpg

Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net dollar gains (Change) and very low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows APOL with a dollar gain Monday of +$4.65 and a Friction Factor of 442 shares. That means that it only took 442 more shares of buying than selling to move APOL higher by one penny. The Market Makers are currently allowing the stock to rise quickly (low friction). The combination of low friction and positive market direction can drive prices higher much faster than normal.

OSI Pharmaceuticals, Inc. (NASDAQ: OSIP), a biotechnology company, discovers, develops, and commercializes molecular targeted therapies for oncology, diabetes, and obesity in the United States and internationally. Its flagship product, Tarceva (erlotinib) is a small molecule inhibitor of the epidermal growth factor receptor, which is used for the treatment of advanced non-small cell lung cancer, as well as for the treatment of patients with locally advanced and metastatic pancreatic cancer. The company also offers Macugen for the treatment of neovascular age-related macular degeneration; and Novantrone, an anthracenedione used as an intravenous chemotherapy agent, as well as for the treatment of acute non-lymphocytic leukemia, and the relief of pain associated with hormone refractory prostate cancer. OSI Pharmaceuticals also has oncology pipeline of molecular targeted therapies in clinical and pre-clinical development, which include OSI-906, an insulin-like growth factor 1 receptor inhibitor implicated in various tumor types; and OSI-027, a mammalian target of rapamycin kinase inhibitor. In addition, the company has research and development programs in diabetes and obesity, including PSN821, an orally administered G protein-coupled receptor 119, agonist with anti-diabetic and appetite suppressing features; and PSN602, an oral dual serotonin and noradrenaline reuptake inhibitor and 5-HT1A agonist for the treatment of obesity. Further, it develops OSI-930, a tyrosine kinase inhibitor designed to target the suppression of both cancer cell proliferation and blood vessel growth, or angiogenesis, in selected tumors; OSI-632, an inhibitor of vascular endothelial growth factor receptor-2; and CP-868,596, a PDGFR inhibitor that is in Phase I trials. OSI Pharmaceuticals has collaboration agreements with Genentech, Inc.; Roche; AVEO Pharmaceuticals, Inc.; and Dako Denmark A/S. The company was founded in 1983 and is headquartered in Melville, New York.

Apollo Group, Inc. (NASDAQ: APOL), through its subsidiaries, provides various educational programs and services at high school, college, and graduate levels. Its subsidiaries include The University of Phoenix, Inc. (University of Phoenix), Institute for Professional Development (IPD), The College for Financial Planning Institutes Corporation (CFP), Western International University, Inc. (Western International University), Insight Schools, Inc. (Insight Schools), Apollo Global, Inc. (Apollo Global), and Meritus University (Meritus). University of Phoenix offers associates, bachelors, masters, and doctoral degree programs in arts and sciences, business and management, criminal justice, education, human services, health care, technology, and communication at campuses and learning centers in 39 states and the District of Columbia, Puerto Rico, Canada, Mexico, and the Netherlands, as well as through online educational delivery system. IPD provides program development and management consulting services, including degree program design, curriculum development, market research, student recruitment, accounting, and administrative services to private colleges and universities in 21 states. CFP provides financial planning education programs, including the certified financial planner professional education program certification, and certification programs in retirement, asset management, and other financial planning areas. Western International University offers undergraduate and graduate degree programs at Arizona campus locations, online, and also through various joint educational agreements in China and India. Insight Schools offers curriculum and administrative services to public schools to operate full-time online high school programs in 10 states. Apollo Global focuses on the provision of education services. Meritus provides degree programs online to working professionals in Canada and internationally. The company was founded in 1973 and is headquartered in Phoenix, Arizona.

Terra Nitrogen Company, L.P. (NYSE: TNH), through its subsidiary, Terra Nitrogen, Limited Partnership, engages in the production and distribution of nitrogen fertilizer products to agricultural and industrial markets. The companys products include anhydrous ammonia, a form of nitrogen fertilizer and the feedstock for the production of other nitrogen fertilizers; and urea ammonium nitrate, a liquid fertilizer. It sells its products primarily in the Central and Southern Plains and the Corn Belt regions of the United States. The companys customers include dealers, national farm retail chains, distributors, and other fertilizer producers and traders. Terra Nitrogen GP, Inc. serves as the general partner of the company. The company was founded in 1991 and is based in Sioux City, Iowa. Terra Nitrogen Company, L.P. is a subsidiary of Terra Nitrogen Corporation.

Humana, Inc. (NYSE: HUM | Quote | Chart | News | PowerRating) provides various health and supplemental benefit plans for employer groups, government benefit programs, and individuals in the United States. It operates in two segments, Government and Commercial. The Government segment includes beneficiaries of government benefit programs. These programs include Medicare, a federal program that provides hospital and medical insurance benefits to persons of age 65 and over, and some disabled persons under the age of 65; Military Services that comprises its TRICARE South Region contract, which provide health insurance coverage to the dependents of active duty military personnel and to retired military personnel and their dependents; and Medicaid, a federal program that facilitate the delivery of health care services primarily to low-income residents. The Commercial segment consists of members enrolled in its medical and specialty products marketed to employer groups and individuals. Its products comprise smart plans and other consumer products, such as Health Maintenance Organization (HMO) products that provide prepaid health insurance coverage to its members through a network of independent primary care physicians, specialty physicians, and other health care providers; Preferred Provider Organization (PPO) products, which are offered primarily to employer groups and individuals; and Administrative Services Only (ASO) products to employers who self-insure their employee health plans. This segment also provides various specialty products, including dental, vision, and other supplemental products. As of December 31, 2007, Humana had approximately 11.5 million members in medical benefit programs and approximately 6.8 million members in specialty product programs. The company was founded in 1964 and is headquartered in Louisville, Kentucky.

Biogen Idec, Inc. (NASDAQ: BIIB | Quote | Chart | News | PowerRating) engages in the development, manufacture, and commercialization of novel therapies primarily in the areas of oncology, neurology, immunology, and cardiology in the United States and internationally. Its products include AVONEX for the treatment of relapsing forms of multiple sclerosis (MS); RITUXAN for the treatment of relapsed or refractory low-grade or follicular, CD20-positive, B-cell non-Hodgkins lymphomas, or B-cell NHLs; TYSABRI for the treatment of relapsing forms of MS; and FUMADERM, an immunomodulator for the treatment of severe psoriasis. The companys other products under development include BG-12, a Phase III clinical trial product for the treatment of MS; Anti-CD80 MAb/galiximab, a Phase III clinical product for relapsed or refractory NHL; Anti-CD23 MAb/lumiliximab, a Phase II/III clinical product for the treatment of relapsed or refractory chronic lymphocytic leukemia; Humanized Anti-CD20 MAb/Ocrelizumab, a Phase III clinical product for the treatment of Rheumatoid Arthritis; and Lixivaptan, a Phase III clinical drug for the treatment of Acute Hyponatremia. In addition, its preclinical stage products include Volociximab, CNF2024, Natalizumab, RAF (BIIB024), CNF3647, Anti CRIPTO, Anti IGF-1R, Daclizumab, CDP-323, BIIB014, Neublastin, Baminercept-alfa, Anti-TWEAK, anti-CD40L Fab, ADENTRI, Aviptadil, and Long acting rFactor IX. Biogen Idec has collaboration agreements with PDL BioPharma, Inc.; Sunesis Pharmaceuticals, Inc.; Vernalis plc; Vetter Pharma-Fertigung GmbH & Co. KG; Elan Corporation plc; Alnylam Pharmaceuticals, Inc.; UCB SA; Neurimmune SubOne AG; Cardiokine Biopharma LLC; and Schering AG. The company was founded in 1985 and is based in Cambridge, Massachusetts.

Express Scripts, Inc. (NASDAQ: ESRX | Quote | Chart | News | PowerRating) offers a range of pharmacy benefit management services in North America. The company provides retail network pharmacy management, retail drug card programs, home delivery pharmacy services, benefit design consultation, drug utilization review, drug formulary management programs, and compliance and therapy management programs. It also offers various specialty services, including patient care and direct specialty home delivery to patients; distribution of injectable drugs to patient homes and physician offices; distribution of pharmaceuticals and medical supplies to providers and clinics; third party logistics services for contracted pharmaceutical manufacturer clients; fertility services to providers and patients; and bio-pharmaceutical services, such as marketing, reimbursement, and customized logistics solutions. In addition, the company provides services, which include distribution of specialty pharmaceuticals requiring special handling or packaging; distribution of pharmaceuticals to low-income patients through manufacturer-sponsored patient assistance programs and company-sponsored generic patient assistance programs; and distribution of sample units to physicians and verification of practitioner licensure. It serves health maintenance organizations, health insurers, third-party administrators, employers, union-sponsored benefit plans, workers compensation plans, and government health programs. The company was founded in 1986 and is headquartered in St. Louis, Missouri.

About BUYINS.NET

WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.

BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2,400,000,000 short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each month's short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. None of the companies in this report have paid to be included in this report. From time to time we will mention a company that may have previously paid $995 per month for market data purchased from BUYINS.NET. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

BUYINS.NET, FRICTION FACTOR and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of BUYINS.NET, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.

By visiting BUYINS.NET or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. BUYINS.NET, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to BUYINS.NET and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.

Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. BUYINS.NET does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. BUYINS.NET places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

CONTACT: Thomas Ronk, CEO, BUYINS.NET WWW: http://www.buyins.net e-mail: Tom@buyins.net Tel: +1 800 715 9999

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index